Artificial intelligence and machine learning (AI/ML) are quickly becoming the norm in biopharma, with now the vast majority of drug companies implementing the technology in some way or another. Most of that has been in drug discovery and development, but it is also moving into manufacturing, marketing and regulatory functions. But as use expands, there are associated risks that companies will have to mitigate, including in areas such as data privacy, cybersecurity and intellectual property.
As AI Use Grows Among Biopharmas, So Do Concerns
AI/ML is becoming increasingly widespread across the industry, but there are concerns about intellectual property that have arisen when most patent laws require inventors to be human.
More from AI
More from Scrip
• By
The Danish firm is spending nearly $580m to repurchase up to 2.2 million shares
• By
The Texas-based firm is giving up on the investigational Alzheimer’s therapy after a second Phase III failure left it with nowhere to go in the disease.
• By
Kyoto-based venture moves HQ to California to expand R&D and business outreach for its regulatory T-cell technology, as it raises around $46m in public and private funding.